Sees FY26 sales growth from continuing operations: flat to 1%; Organic sales growth from continuing operations: approximately flat
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BAX:
- Is BAX a Buy, Before Earnings?
- Baxter: Turnaround Progress but Muted 2026 Outlook Keeps Hold Rating and $22 Price Target Unchanged
- Baxter showcases Global Surgical Solutions portfolio at AORN Conference
- Baxter price target lowered to $22 from $23 at Evercore ISI
- Baxter introduces IV Verify Line Labeling System